Faculty Rank: Professor
Medical or Graduate Education:
Medical College of Pennsylvania
Rush University Medical Center - Hematology
Rush University Medical Center - Hematology
Blood disorders, noncancerous
Bone marrow biopsy
Cutaneous T-cell lymphoma (CTCL)
Hairy cell leukemia
Leukemias, acute and chronic
Myelodysplastic syndrome (MDS)
Targeted therapy for hematologic cancer
Translational research and targeted therapies for:
Acute and chronic leukemias
Consultants In Hematology Professional Building 1725 W. Harrison St. Suite 1010 Chicago, IL 60612 Phone: (312) 563-2320 Fax: (312) 563-2480
View Larger Map • Driving Directions
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW J. Clin. Oncol. 2014 May 5 Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Dakhil S, Hermann R, Schreeder MT, Gregory SA, Monte M, Windsor KS, Hurst D, Chai A, Brewster M, Richards P Leuk. Lymphoma 2014 Mar 7 Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM. Dimopoulos M, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP Blood 2014 Jul 15 Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Ruan J, Gregory SA, Christos P, Martin P, Furman RR, Coleman M, Leonard JP Clin Lymphoma Myeloma Leuk 2014 Apr 14(2):107-13. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI J. Clin. Oncol. 2013 Oct 14 Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd. J Leukoc Biol. 2013 2013 Jan 93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7. Successful Treatment of Hepatosplenic T-Cell Lymphoma With ESHAP Followed by Autologous Stem Cell Transplant. Chalmers AW, Katz DA, Miller IJ, Gregory SA. Clin Adv Hematol Oncol. 2013 2013 Feb 11(2):109-13. No abstract available. Ocular Adnexal MALTomas: Case Series of Patients Treated With Primary Radiation. Russell W, Herskovic A, Gessert D, Cohen JA, Rubenstein JB, Gregory SA. Clin Adv Hematol Oncol. 2013 2013 Apr 11(4):209-14. CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1. Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC. Exp Hematol. 2012 2012 Nov 40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. Blood. 2012 2012 Jan 19 119(3):692-5. doi: 10.1182/blood-2011-09-378414. Epub 2011 Nov 23. Analysis of very elderly (â‰¥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Br J Haematol. 2012 2012 Jan 156(2):196-204. doi: 10.1111/j.1365-2141.2011.08934.x. Epub 2011 Nov 16. Relapsed diffuse large B-cell lymphoma--10 years later. Jain S, Shah N, Gregory S. Clin Adv Hematol Oncol. 2011 2011 Sep 9(9):704-8. No abstract available. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clin Adv Hematol Oncol. 2011 2011 Sep 9(9 Suppl 22):1-16. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P. Leuk Lymphoma. 2011 2011 Nov 52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24. In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice. Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd. Exp Hematol. 2011 2011 May 39(5):580-590.e1. doi: 10.1016/j.exphem.2011.01.012. Epub 2011 Feb 1. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press O, Zelenetz AD. Leuk Lymphoma. 2011 2011 Jul 52(7):1188-99. doi: 10.3109/10428194.2011.570396. Epub 2011 May 23. Review. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Clin Lymphoma Myeloma Leuk. 2011 2011 Dec 11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22. Multiple myeloma with multiple extramedullary plasmacytomas. Nangia JR, Lakhani AA, Loew JM, Gregory SA. Clin Adv Hematol Oncol. 2011 2011 Aug 9(8):630-2. No abstract available. Bendamustine's emerging role in the management of lymphoid malignancies. Rummel MJ, Gregory SA. Semin Hematol. 2011 2011 Apr 48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review. Intravascular B-cell lymphoma following nodal diffuse large B-cell lymphoma. Katz DA, Miller IJ, Gregory SA. Clin Adv Hematol Oncol. 2010 2010 Sep 8(9):637-41. No abstract available. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Czuczman MS, Gregory SA. Leuk Lymphoma. 2010 2010 Jun 51(6):983-94. doi: 10.3109/10428191003717746. Review. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. J Clin Oncol. 2010 2010 Feb 20 28(6):1038-46. doi: 10.1200/JCO.2009.25.4961. Epub 2010 Jan 19. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Blood. 2010 2010 Apr 1 115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL. J Clin Oncol. 2009 2009 Oct 20 27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21. Long-term outcomes to fludarabine and rituximab in WaldenstrÃ¶m macroglobulinemia. Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E. Blood. 2009 2009 Apr 16 113(16):3673-8. doi: 10.1182/blood-2008-09-177329. Epub 2008 Nov 17. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Oncologist. 2009 2009 14 Suppl 2:4-16. doi: 10.1634/theoncologist.2009-S2-4. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. Oncologist. 2009 2009 14 Suppl 2:52-4. doi: 10.1634/theoncologist.2009-S2-52. Review. No abstract available. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction. Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. Oncologist. 2009 2009 14 Suppl 2:1-3. doi: 10.1634/theoncologist.2009-S2-1. No abstract available. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA Leukemia 2008 May 22(5):998-1006 Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD. Clin Adv Hematol Oncol. 2008 2008 Jun 6(6):437-45. Review. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd. Transfusion. 2008 2008 Dec 48(12):2638-44. doi: 10.1111/j.1537-2995.2008.01926.x. Epub 2008 Sep 16. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P. Clin Adv Hematol Oncol. 2008 2008 Aug 6(8):587-90. Review. No abstract available. Localized bone disease as a presentation of hairy cell leukemia. Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S. Clin Adv Hematol Oncol. 2008 2008 Apr 6(4):290-4. No abstract available.
Patient feedback information is available for physicians employed by Rush University Medical Center who have received
30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the
section of the Rush University Medical Center website.
To watch a brief video of Stephanie A. Gregory, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
We’re gonna cure one cancer at a time. And it’s gonna be one cancer with a new drug, a new, targeted therapy. We’re going away from many intravenous chemotherapy drugs to pills. There’s one leukemia today that was a hundred percent fatal within three years when I was doing my training many years ago. Today that is cured with a pill that patients take. We now have a 95 percent 10-year survival of those patients. So I’ve seen many, many changes over the years, especially in the area that I work in: the lymphomas, the lukemias, the myelomas. Great progress.
We always say we have the best relationships with our patients because we actually love each other. And the best thing I can ever say to a patient is, “You’re cured.” And that really makes my day.